Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Versus Standard-Dose TMP-SMX for PJP Prevention After Kidney Transplantation
NCT07619027Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
Phase 4, randomised trial of trimethoprim + sulfamethoxazole in Pneumocystis jirovecii pneumonia (PJP) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Incidence of Pneumocystis jirovecii pneumonia at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
Pneumocystis jirovecii pneumonia (PJP)
Beyond the preview
Go deeper on NCT07619027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619027.